Latest gout Stories
Mara McAdams DeMarco, Ph.D. of Johns Hopkins Medical Institutions in Maryland was awarded $100,000 to pursue her research on the risk factors and consequences of gout, a form of arthritis, in older adults. The Arthritis National Research Foundation (ANRF) and the American Federation for Aging Research (AFAR) jointly funded her work in their first-time collaboration of the Arthritis and Aging Research Grant. Long Beach, CA and New York, NY (PRWEB) May 07, 2013 Mara McAdams DeMarco, Ph.D....
The newest blog from Marble Media LLC’s HealthFill.com website reviews a Journals of Gerontology study’s discovery that the Mediterranean Diet benefits older adults by reducing medical conditions related to elevated serum uric acid concentrations. FORT LEE, New Jersey, (PRWEB) April 29, 2013 The latest blog from health and medical website Healthfill.com titled “The Medierranean Diet’s Benefits for Older Adults” takes a look at a recent study from the Journals of Gerontology on...
According to a study published in the Journals of Gerontology Series A: Biological Sciences and Medical Sciences, a baseline adherence to a Mediterranean diet (MeDiet) is associated with a lower risk of hyperuricemia, defined as a serum uric acid (SUA) concentration higher than 7mg/dl in men and higher than 6mg/dl in women. Hyperuricemia has been associated with metabolic syndrome, hypertension, type 2 diabetes mellitus, chronic kidney disease, gout, and cardiovascular morbidity and...
Patients and doctors encouraged to discuss target uric acid levels and appropriate treatment plan to avoid gout flares and long-term complications PITTSBURGH, March 12, 2013 /PRNewswire/ -- The Gout & Uric Acid Education Society (GUAES) has added six new educational videos for patients and medical professionals to its library of popular educational videos on gout, highlighting the society's most important takeaways from the recently released American College of Rheumatology (ACR)...
DEERFIELD, Ill. and OSAKA, Japan, Dec. 17, 2012 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda's wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) has entered into a definitive agreement with Caraco Pharmaceutical Laboratories, Ltd. (Caraco), a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd for the sale of the non-Colcrys (colchicine, USP) URL Pharma, Inc.* generic business. With the acquisition of URL...
BRIDGEWATER, N.J., Nov. 13, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced results from new post-hoc analyses of KRYSTEXXA(®) (pegloticase) pivotal Phase III and open-label extension trials that reinforced the health-related quality of life (HRQOL) benefits of KRYSTEXXA treatment in adult patients with refractory chronic gout (RCG), including tophus reduction outcomes. New data also demonstrated that guidance on measuring serum uric acid (sUA)...
Use of gut bacteria to treat autoimmune diseases among other research presented at ACR Refuting a belief long held by many physicians, a Mayo Clinic study found that rheumatoid arthritis patients also can get gout. The research is among several studies Mayo Clinic is presenting at the American College of Rheumatology annual meeting in Washington. Researchers also found that gut bacteria has potential to treat autoimmune disorders, rheumatoid arthritis patients are at higher risk for...
BRIDGEWATER, N.J., Nov. 12, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that new data from an open-label extension (OLE) study published in the Annals of the Rheumatic Diseases reinforced the safety and efficacy profile of KRYSTEXXA(®) (pegloticase) treatment for refractory chronic gout (RCG) over the long-term. OLE data aligned with outcomes seen in the KRYSTEXXA pivotal Phase III clinical trials, with no new safety signals identified....
BRIDGEWATER, N.J. and DUBLIN, Oct. 19, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) and its wholly owned subsidiary, Savient Pharma Ireland Limited, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has completed its scientific assessment and has issued a positive opinion recommending approval of a marketing authorization in the European Union for KRYSTEXXA(®) (pegloticase) for the treatment of...
NORWALK, Conn., Oct. 19, 2012 /PRNewswire/ -- UBM Medica US announces that Musculoskeletal Network features special coverage of new gout guidelines from the American College of Rheumatology, including the first recommendations on genetic testing for adverse reactions to a drug commonly used to treat the condition. The prevalence of gout has risen substantially over the last 20 years in the United States, and now affects 8.3 million Americans, or about 4% of the US population....
